LQDA
NASDAQ
US
Liquidia Corporation - Common Stock
$37.68
▲ +$0.21
(+0.56%)
Vol 786K
6
Quality Score
fail
Rev ✗
NI ✗
>IPO ✗
Mkt Cap
$3.0B
ROE
-296.8%
Margin
-176.0%
D/E
872.92
Beta
0.47
52W
$11–$36
Wall Street Consensus
15 analysts · Apr 20266
Strong Buy
7
Buy
1
Hold
0
Sell
1
Strong Sell
86.7%
Buy Rating
Price Chart
Similar Stocks
AMRX
Amneal Pharmaceuticals Inc
P/E 671.4
$4.0B
CRNX
Crinetics Pharmaceuticals Inc
$4.4B
INDV
Indivior Pharmaceuticals, Inc
P/E 35.8
$4.5B
GPCR
Structure Therapeutics Inc
$4.2B
EWTX
Edgewise Therapeutics Inc
$2.6B
TARS
Tarsus Pharmaceuticals Inc
$3.5B
SUPN
Supernus Pharmaceuticals Inc
$2.8B
ALMS
Alumis Inc
$1.0B
AMRX
Amneal Pharmaceuticals Inc
P/E 671.4
$4.0B
Earnings
Beat rate: 25.0%
Next Report
May 06, 2026
EPS Estimate: $0.36
| Quarter | EPS Est | EPS Act | Surprise |
|---|---|---|---|
| Mar 2026 | $0.36 | — | — |
| Dec 2025 | $0.18 | $0.17 | $-0.01 |
| Sep 2025 | $-0.41 | $-0.04 | +$0.37 |
| Jun 2025 | $-0.44 | $-0.49 | $-0.05 |
Fundamentals Trend
| Metric | 2025-06-30 | 2025-09-02 | 2025-10-02 | 2025-11-03 | 2025-12-03 | 2026-01-02 |
|---|---|---|---|---|---|---|
| ROE (TTM) | -223.9% | -223.9% | -223.9% | -223.9% | -296.8% | -296.8% |
| P/E (TTM) | — | — | — | — | — | — |
| Net Margin | -470.5% | -732.2% | -732.2% | -732.2% | -176.0% | -176.0% |
| Gross Margin | 83.1% | 69.3% | 69.3% | 69.3% | 89.1% | 89.1% |
| D/E Ratio | 1274.67 | 1274.67 | 1274.67 | 1274.67 | 872.92 | 872.92 |
| Current Ratio | 2.49 | 2.49 | 2.49 | 2.49 | 2.20 | 2.20 |
Key Ratios
ROA (TTM)
-49.2%
P/S (TTM)
43.35
P/B
12.9
EPS (TTM)
$-1.43
CF/Share
$-0.86
Rev Growth 3Y
+2.9%
52W High
$36.41
52W Low
$11.26
$11.26
52-Week Range
$36.41
How does LQDA compare to Pharmaceuticals peers?
Peer group: Mid-cap Pharmaceuticals ($2B+) · 25 companies
LQDA valuation vs Pharmaceuticals peers
P/E ratio
—
▼
0%
below
peers
(30.7)
vs Peers
vs Industry
Fair value
P/S ratio
43.4
▲
545%
above
peers
(6.7)
vs Peers
vs Industry
Overvalued
P/B ratio
12.9
▲
148%
above
peers
(5.2)
vs Peers
vs Industry
Overvalued
Div yield
—
▼
0%
below
peers
(3.1%)
vs Peers
vs Industry
Low yield
LQDA profitability vs Pharmaceuticals peers
ROE
-296.8%
▼
1038%
below
peers
(-26.1%)
vs Peers
vs Industry
Weak
Net margin
-176.0%
▼
12041%
below
peers
(-1.5%)
vs Peers
vs Industry
Weak
Gross margin
89.1%
▲
0%
above
peers
(88.9%)
vs Peers
vs Industry
Weak
ROA
-49.2%
▼
420%
below
peers
(-9.5%)
vs Peers
vs Industry
Weak
LQDA financial health vs Pharmaceuticals peers
D/E ratio
872.9
▲
3092%
above
peers
(27.4)
vs Peers
vs Industry
High debt
Current ratio
2.2
▼
37%
below
peers
(3.5)
vs Peers
vs Industry
Low liquidity
Beta
0.5
▼
20%
below
peers
(0.6)
vs Peers
vs Industry
More volatile
LQDA fundamentals radar
LQDA
Peer median
Industry
LQDA profitability vs leverage
Bubble size = market cap · X = net margin · Y = D/E ratio